The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Andrew J. Cowan on Frontline Therapy of Multiple Myeloma: Advances from ASH 2025
By The Cancer News Team
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
Dr. Andrew J. Cowan on Frontline Therapy of Multiple Myeloma: Advances from ASH 2025
By The Cancer News Team
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
Dr. Andrew J. Cowan on Frontline Therapy of Multiple Myeloma: Advances from ASH 2025
By The Cancer News Team
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
Dr. Thomas DeLoughery on Evolving Treatment Strategies in Immune Thrombocytopenia
By The Cancer News Team
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
Dr. Thomas DeLoughery on Evolving Treatment Strategies in Immune Thrombocytopenia
By The Cancer News Team
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
Dr. Thomas DeLoughery on Evolving Treatment Strategies in Immune Thrombocytopenia
By The Cancer News Team
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.